Mélanie Simony
7 Papers
42 Citations
Mélanie Simony is an academic researcher. The author has contributed to research in topics: Cohort & Hepatitis C. The author has an hindex of 5, co-authored 7 publications.
Chat about Author
Papers
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study
Fabrice Carrat,Hélène Fontaine,Céline Dorival,Mélanie Simony,Alpha Diallo,Christophe Hézode,Victor de Ledinghen,Dominique Larrey,Georges Haour,Jean-Pierre Bronowicki,Fabien Zoulim,Tarik Asselah,Patrick Marcellin,Dominique Thabut,Vincent Leroy,Albert Tran,François Habersetzer,Didier Samuel,Dominique Guyader,Olivier Chazouillères,Philippe Mathurin,Sophie Metivier,Laurent Alric,Ghassan Riachi,Jérôme Gournay,Armand Abergel,Paul Calès,Nathalie Ganne,Véronique Loustaud-Ratti,Louis d’Alteroche,Xavier Causse,Claire Geist,Anne Minello,Isabelle Rosa,Moana Gelu-Simeon,Isabelle Portal,François Raffi,Marc Bourlière,Stanislas Pol +38 more
TL;DR: Treatment with direct-acting antivirals is associated with reduced risk for mortality and hepatocellular carcinoma and should be considered in all patients with chronic HCV infection.
550
LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather
Hélène Fontaine,Christophe Hézode,Fabien Zoulim,Didier Samuel,M. Bourlière,G. Haour,C. Dorival-Mouly,Vincent Leroy,V. de Ledinghen,S. Lucier,Dominique Larrey,Albert Tran,S. Metivier,Yves Benhamou,I. Hubert-Fouchard,François Habersetzer,Patrick Marcellin,P. Mathurin,Laurent Alric,Jean-Pierre Bronowicki,Dominique Guyader,Véronique Loustaud-Ratti,Anne Minello,Ghassan Riachi,Isabelle Rosa,Mélanie Simony,Alpha Diallo,Fabrice Carrat,Stanislas Pol +28 more
TL;DR: In this paper, the preliminary results of the Sofosbuvir-based combinations with DCV or SIM, with or without ribavirin (RBV), in Genotype 4-infected patients were reported.
33
The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
Clovis Lusivika-Nzinga,Hélène Fontaine,Céline Dorival,Mélanie Simony,Stanislas Pol,Fabrice Carrat,Anrs +6 more
TL;DR: Overall, a constant decrease in the risk of occurrence of HCC was found from the start of treatment, and these findings support the urgent initiation of DAAs in all patients.
27
Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55-70 Study.
Alain Makinson,Alain Makinson,Jonathan Dubois,Sabrina Eymard-Duvernay,Pascale Leclercq,Olivia Zaegel-Faucher,Louis Bernard,Matteo Vassallo,Claudine Barbuat,Christian Geny,Eric Thouvenot,Dominique Costagliola,Anna Ozguler,Marie Zins,Mélanie Simony,Jacques Reynes,Jacques Reynes,Claudine Berr +17 more
TL;DR: In this matched study of aging individuals, HIV was significantly associated with an increased risk of NCI after adjusting for major confounders and results were confirmed with more stringent NCI classifications.
24
High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study
Lionel Piroth,Hubert Paniez,Anne Marie Taburet,Corine Vincent,Eric Rosenthal,Karine Lacombe,Eric Billaud,David Rey,David Zucman,François Bailly,Jean-Pierre Bronowicki,Mélanie Simony,Alpha Diallo,Jacques Izopet,Jean-Pierre Aboulker,Laurence Meyer,Jean-Michel Molina +16 more
TL;DR: In HIV/HCV genotype 1/4-coinfected null responders, a 24-week regimen combining daclatasvir, asunaprevir, and peg-IFN/RBV was associated with a very high cure rate and the safety profile was acceptable, even though cirrhotic patients with low albuminemia and platelets should be monitored closely.
15